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LRRK2 Haplotype Analyses in European and North
African Families with Parkinson Disease: A Common
Founder for the G2019S Mutation Dating
from the 13th Century
To the Editor:
Parkinson disease [PD (MIM 168600)] is the second most
common neurodegenerative disorder, characterized by
resting tremor, rigidity, bradykinesia, and gait distur-
bances. The LRRK2 gene (GenBank accession number
AY792511) was recently identified as being responsible
for autosomal dominant PD (Paisan-Ruiz et al. 2004;
Zimprich et al. 2004). Several groups have reported that
a single pathogenic G6055A substitution (G2019S) in
the LRRK2 gene was associated with 3%–6% and 1%–
2% of familial and sporadic PD, respectively (Di Fonzo
et al. 2005; Gilks et al. 2005; Kachergus et al. 2005;
Lesage et al. 2005; Nichols et al. 2005). In addition,
Kachergus et al. (2005) demonstrated that, in 13 families
of European descent, G2019S-mutation carriers shared
a small ancestral haplotype, suggestive of a common
founder.
In our sample of 198 affected probands from families
with PD that is compatible with autosomal dominant in-
heritance, mostly from France and North Africa, we iden-
tified a total of 13 LRRK2 G2019S-mutation carriers,
one of whom was homozygous for this mutation. Five
were of European descent (two from France and one each
from Portugal, Belgium, and The Netherlands), one was
from North America, and seven were from North Africa.
Surprisingly, one 60-year-old healthy French control in-
dividual also carried the same mutation.
To determine whether a common haplotype was also
shared by the G2019S carriers in our series, all available
family members of the 14 LRRK2-positive families were
genotyped for the 17 chromosome 12q microsatellite
markers and four SNPs, described elsewhere (Kachergus
et al. 2005), that span a 16-Mb region that includes the
LRRK2 gene. Seven markers (three microsatellites and
four SNPs) were located within the gene. A total of 62
individuals were analyzed: 40 G2019S carriers (23 af-
fected and 17 unaffected) and 22 noncarriers, 2 of whom
were affected. The microsatellites were genotyped by mul-
tiplexing appropriate labeled primers. The fluorescent
PCR products were then pooled for analysis, in two runs,
on an ABI 3730 automated sequencer. Results were an-
alyzed with GeneMapper 3.5 software (Applied Biosys-
tems). Two DNA samples from CEPH reference families
1331-01 and 1331-02 were used as external standards,
to control for consistency between runs. The four LRRK2
SNPs were genotyped by using the SnapShot multiplex
kit (Applied Biosystems), in accordance with the manu-
facturer’s instructions. Haplotypes were constructed us-
ing the Merlin program (Abecasis et al. 2002; Center
for Statistical Genetics), and their frequencies were es-
timated with the expectation-maximization algorithm
(Excoffier and Slatkin 1995). The difference in haplotype
distribution between mutation carriers and noncarriers
was evaluated by x2 and Fisher’s exact tests. Marker-
allele frequencies and marker positions were described
elsewhere (Kachergus et al. 2005). The age of the mu-
tation was evaluated by estimating the age of the most
recent common ancestor of the G2019S-mutation car-
riers on the basis of information from their shared hap-
lotypes (Genin et al. 2004).
The LRRK2 haplotype that was associated with the
G2019S mutation in all families originating from Europe
and North Africa (fig. 1) was consistent with that de-
scribed by Kachergus et al. (2005). However, the shared
region was smaller than the 145–154 kb previously pub-
lished, which reduces the common haplotype to only 60
kb. This minimal haplotype (T-254-A-G-A-154) con-
sisting of six adjacent markers spanning the region be-
tween SNP rs7966550 (Entrez SNP) in exon 22 of the
LRRK2 gene and microsatellite marker D12S2518 in
intron 45 flanking the G2019S mutation in exon 41 was
determined in French family 030, in which 29 members
in two generations were available for study. Parental
phases could also be unambiguously determined in six
other families. In the remaining families, the haplotype
could not be reconstructed unambiguously from the
shared region, but the genotypes were all compatible
with the presence of the common haplotype. In the ma-
jority of families, the shared region extended farther than
the minimal haplotype, particularly 3′ of the LRRK2
gene, and independent of geographical origin. The com-
mon haplotype was also shared by five (24.7%) non-
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Figure 1 Genotypes for chromosome 12q12 markers in the disease haplotype in subjects from 14 LRRK2-positive families. The sequences
of the microsatellites and SNPs were from the GDB Human Genome Database and Entrez SNP, respectively. An asterisk (*) indicates an
unaffected individual from the control population who carried the G2019S mutation. A double asterisk (**) indicates a homozygous G2019S
carrier. For families in which phase could not be unambiguously determined, both alleles are shown. The haplotype shared by all G2019S
carriers is highlighted in gray.
carriers of the G2019S mutation. However, the minimal
haplotype was significantly more frequent in mutation
carriers (7/7) than in noncarriers (5/21) ( ;2x p 12.44
), even when only the seven families in whichP ! .001
the G2019S haplotype could be unambiguously deter-
mined were taken into account.
This finding, in addition to previous data, extends the
potential founder effect observed in Norwegians, Irish,
Polish, and Americans of European descent to other Eu-
ropean countries (France, Belgium, Portugal, and The
Netherlands) and to three countries in North Africa (Al-
geria, Morocco, and Tunisia). The widespread distribu-
tion of the founder effect in Europe and its extension to
North Africa prompted us to evaluate the time at which
the mutation event might have occurred. Using patients
for whom extended haplotypes could be unambiguously
determined in our study (from families 030, 755, 021,
and 400) and the study of Kachergus and his collabo-
rators (2005) (from families P-063 and 1120), we esti-
mated that the mutation occurred 29 generations earlier
(95% CI 15–55). If a generation is defined as 25 years,
the mutation occurred 725 (95% CI 375–1375) years
ago, in the 13th century.
In conclusion, we have extended the founder effect for
the LRRK2 G2019S mutation to other European coun-
tries and to North Africa, and we have reduced the com-
mon ancestral haplotype to a 60-kb region. The most
recent common ancestor probably lived ∼725 years ago.
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